Saruplase fibrinolysis

Description Results NMA

Mortalité à long terme 0.86 [0.69; 1.08]

Hémorragies majeures précoces 0.84 [0.53; 1.34]

Mortalité précoce 0.85 [0.64; 1.12]

AVC précoce 1.00 [0.56; 1.80]

Hémorragies majeures précoces 1.10 [0.62; 1.97]

Haemorraghic stroke 1.00 [0.14; 7.07]

Mortalité précoce 1.23 [0.52; 2.91]

AVC précoce 0.80 [0.22; 2.95]

reinfarction 1.00 [0.43; 2.37]

saruplase 20-mg bolus and 60-mg infusion over 60 min (n=1542)

vs.

streptokinase 1.5-MU infusion over 60 min (n=1547)

double blind

Parallel groups

Sample size: 1542/1547

Primary endpoint: death 30d

FU duration: 1 y

sarupalse 20 mg bolus followed by 60 mg infusion for 60 min (n=198)

vs.

1.5 million IU streptokinase infused over 60 min (n=203)

double blind

Parallel groups

Sample size: 198/203

Primary endpoint: patency

FU duration: ND

saruplase 80 mg/hour (n=236)

vs.

alteplase 100 mg every 3 hours (n=237)

open

Parallel groups

Sample size: 236/237

Primary endpoint: patency

FU duration: hospital stay

20 mg bolus followed by 60 mg infusion for 60 min (n=198)

vs.

80 mg recombinant pro-urokinase (n=-9)

double blind

Parallel groups

Sample size: 198/-9

Primary endpoint:

FU duration: